Almac is to announce the extension of its site-specific PEGylation technology to cover single domain antibody fragments at Bio 2010, the annual Bio Industry Association convention.
In exemplifying the site-specific PEGylation technology with single domain antibodies and interferons, Almac said it has demonstrated that therapeutically important complex biological proteins can be engineered to offer viable candidates for development as therapeutic agents.
Existing PEGylation technologies produce products that are PEGylated at multiple sites in an uncontrolled manner.
Inevitably, this results in heterogeneous population of PEGylated molecules and a net decrease in potency compared with the un-PEGylated analogue.
The Almac approach allows the specific PEGylation site to be selected and controlled and generates a homogeneous PEGylated product.
The outcome, compared with existing PEGylation techniques, is improved efficacy, which leads to lower dose levels and consequently lower cost of goods; while still providing improved ADME profile due to the addition of the PEG moiety.
